Exagen (NASDAQ:XGN - Get Free Report) had its price target upped by equities researchers at Canaccord Genuity Group from $8.00 to $11.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Canaccord Genuity Group's price target would suggest a potential upside of 27.46% from the stock's current price.
Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald decreased their price objective on shares of Exagen from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Craig Hallum started coverage on shares of Exagen in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 price objective for the company. BTIG Research reiterated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. UBS Group reissued an "overweight" rating on shares of Exagen in a research report on Thursday, May 15th. Finally, KeyCorp raised shares of Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 target price for the company in a research report on Wednesday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Exagen presently has a consensus rating of "Buy" and a consensus target price of $11.25.
Read Our Latest Report on XGN
Exagen Stock Up 2.7%
Shares of XGN traded up $0.23 on Wednesday, reaching $8.63. The company's stock had a trading volume of 282,684 shares, compared to its average volume of 442,268. The company has a current ratio of 4.95, a quick ratio of 4.95 and a debt-to-equity ratio of 1.06. Exagen has a twelve month low of $1.78 and a twelve month high of $9.10. The stock has a market capitalization of $189.86 million, a PE ratio of -9.70 and a beta of 1.61. The firm has a fifty day moving average of $7.19 and a 200-day moving average of $5.46.
Exagen (NASDAQ:XGN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million. Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. Equities analysts predict that Exagen will post -0.88 EPS for the current year.
Institutional Trading of Exagen
Several institutional investors and hedge funds have recently made changes to their positions in XGN. Acadian Asset Management LLC purchased a new position in Exagen in the 1st quarter worth $25,000. Corient Private Wealth LLC purchased a new stake in shares of Exagen during the fourth quarter worth about $45,000. Virtu Financial LLC purchased a new stake in shares of Exagen during the fourth quarter worth about $46,000. Marshall Wace LLP purchased a new stake in shares of Exagen during the fourth quarter worth about $66,000. Finally, Northern Trust Corp boosted its holdings in shares of Exagen by 16.7% during the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after purchasing an additional 2,630 shares during the period. Hedge funds and other institutional investors own 75.25% of the company's stock.
About Exagen
(
Get Free Report)
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Further Reading
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access